Filling the Gap Between Benchside and Bedside: AI-accelerated Target Discovery to Therapeutic Development by Hideyuki Shimizu

1. LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19

Hideyuki Shimizu, Manabu Kodama, Masaki Matsumoto, Yasuko Orba, Michihito Sasaki, Akihiko Sato, Hirofumi Sawa and Keiichi I. Nakayama

Publication: iScience
Publication Date: 18 November 2022
DOI: https://doi.org/10.1016/j.isci.2022.105314

2. A shift in glutamine nitrogen metabolism contributes to malignant progression of cancer

Manabu Kodama, Kiyotaka Oshikawa, Hideyuki Shimizu, Susumu Yoshioka, Masatomo Takahashi, Yoshihiro Izumi, Takeshi Bamba, Chisa Tateishi, Takeshi Tomonaga, Masaki Matsumoto and Keiichi I. Nakayama 

Publication: Nature Communications
Publication Date: 17 March 2020
DOI: 10.1038/s41467-020-15136-9

3. Artificial intelligence in oncology

Hideyuki Shimizu and Keiichi I. Nakayama

Publication: Cancer Science
Publication Date: 4 March 2020 
DOI: 10.1111/cas.14377

Hideyuki Shimizu, Professor
E-mail: h_shimizu.dsc(at)tmd.ac.jp

Department of AI Systems Medicine, M&D Data Science Center,
Tokyo Medical and Dental University(TMDU)

＊Please change (at) in e-mail addresses to @ on sending your e-mail to contact personnels.